[ad_1]
|
| STAT3 inhibition aptid (APTSTAT3), lipid nanocomposite formation and transdermal administration of psoriasis / atopy treatment regimens (provided by KAIST) © News1 |
Korea Science and Technology Agency (KAIST) Developed successfully peptides that can treat psoriasis and atopy through skin grafting.
The team managed to treat psoriasis in an animal model by making peptides that were discovered many years ago as nanoparticles and pbading them through the skin.
Psoriasis is a chronic inflammatory disease of the skin. 3% is one of the autoimmune diseases that suffer from it.
It has been shown that a protein called STAT3 plays a crucial role in the development of psoriasis.
The team discovered a peptide capable of degrading the function of STAT3 protein several years ago and developing it as an anticancer drug. However, because the skin of psoriasis is so thick, it has been technically challenged to penetrate the peptides through the skin to perform targeted drug treatments.
In this study, two phospholipids and STAT3 inhibitory peptides of different lengths and found stable formation of very small disk-shaped nanoparticles of 30 nanometers (1 nm = 1 billionth of a meter) in size.
With this, the team produced a STAT3 inhibition peptide consisting of disk-shaped nanoparticles of several tens of nanometers in size through a lipid-based formulation.
The STAT3 inhibitor peptides developed by the researchers showed excellent anti-inflammatory effects when administered to animal models of psoriasis and prevented the hyperproliferation of keratinocytes, a key component of psoriasis. , and the secretion of inflammatory cytokines such as IL-17
In collaboration with Professor Kim Filhan of the Graduate School of Medicine, KAIST, the team observed how deeply peptides penetrated into the skin, confirming that the nanoparticles crossed the stratum corneum up to the dermal layer.
"We have confirmed that STAT3 inhibitor of the aptidase may be a candidate for a new biopharmaceutical drug that shows excellent therapeutic effects against psoriasis, a very intractable skin inflammatory disease," he said. Professor Chon Sang-yong. And we expect it to become a clinical application in the future. "
This research was supported by the Global Laboratory Program of the Korea Research Foundation and the Biomedical Technology Development Project.
Dr. Kim Jin-Yong participated as author and published the results of the research in the international scientific journal ACS Nano.) 'Published online 27th of last month
memory444444 @
[ad_2]
Source link
